Locations:
Search
Concurrent treatment necessary for addressing progressive disease and infection
Preliminary results suggest combination therapy with lisaftoclax improves survival with few adverse events in patients with AL amyloidosis and relapsed/refractory multiple myeloma
New system refines classification of cytogenetic abnormalities at time of response assessment and their clinical significance
Lifetime Achievement award-winner reflects on psychosocial support and caregiver readiness
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Questions remain about the merits of asparaginase-based therapy
Phase 1 study found mutant calreticulin-specific monoclonal antibody brings promising results with no dose-limiting toxicities
Age alone should not rule out patients from potentially curative treatment
Discussing research into improving CAR T-cell therapy efficacy
Combination therapy doubles the number of meaningful spleen volume responses over monotherapy
Making sense of the fast-moving treatment landscape
Advertisement
Advertisement